Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Romania (1)

Russia (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

Ukraine (1)

United Arab Emirates (1)

18.07.2022
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy

The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® 

Read more

08.07.2022
STADA Health Report 2022: Europe experiencing worsening health conditions
STADA Health Report 2022: Europe experiencing worsening health conditions

Self-assessed burnout rates at all-time high; stress levels have increased;
more than one in three are struggling with sleep; appreciation f…

Read more

25.06.2022
People with Parkinson’s are missing out on regular specialist advice in much of Europe
People with Parkinson’s are missing out on regular specialist advice in much of Europe

Many Parkinson’s patients across Europe are missing out on regular specialist advice on treating their condition, according to the findings …

Read more

09.06.2022
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab

Offers a comprehensive range of presentations to the EU adalimumab
biosimilars market

Read more

22.04.2022
STADA brings in Berndt to further develop specialties and biosimilars offerings
STADA brings in Berndt to further develop specialties and biosimilars offerings

Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars

Read more

06.04.2022
Alvotech and STADA pave way to launching HUKYNDRA® (AVT02)
Alvotech and STADA pave way to launching HUKYNDRA® (AVT02)

A citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

Read more

18.03.2022
Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China
Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China

Ignis and STADA’s Britannia sign exclusive licensing agreement to develop and commercialize subcutaneous apomorphine in mainland China, Hong…

Read more

19.01.2022
STADA expands production network with EUR50m project in Romania
STADA expands production network with EUR50m project in Romania

STADA is preparing to meet demand for its expanding portfolio by investing almost EUR50 million in a supply-chain hub in Turda, Romania

Read more

05.01.2022
STADA sets up for success with Erin Federman as global biosimilars commercial head
STADA sets up for success with Erin Federman as global biosimilars commercial head

Experienced expert Erin Federman will oversee commercialization of STADA’s biosimilars portfolio and pipeline

Read more